april
million
case
corona
viru
diseas
report
worldwid
pandem
grow
alarm
rate
nation
govern
struggl
control
local
epidem
scant
diagnost
imperman
nonpharmaceut
intervent
look
addit
epidemiolog
solut
locat
singapor
taiwan
success
slow
epidem
growth
use
intens
surveil
broader
test
strategi
identifi
contain
case
lancet
infecti
diseas
sarah
ee
fang
yong
colleagu
report
three
cluster
case
identifi
singapor
earli
activ
casefind
contact
trace
confirm
rtpcr
one
cluster
church
church
previous
identifi
link
two
import
case
wuhan
china
two
addit
cluster
church
b
famili
gather
attribut
commun
transmiss
sever
acut
respiratori
syndrom
coronaviru
one
individu
interact
cluster
serolog
platform
develop
assess
confirm
antibodi
respons
captur
past
infect
serolog
analysi
yong
colleagu
identifi
miss
link
church
cluster
two
clustersan
individu
twice
test
neg
rtpcr
link
three
cluster
yong
colleagu
highlight
success
surveil
measur
captur
mani
case
effect
slow
spread
singapor
investig
exemplifi
fail
rtpcr
sole
diagnost
method
surveil
inabl
detect
past
infect
ad
valu
serolog
test
captur
within
correct
timefram
diseas
onset
detect
activ
past
infect
public
health
practic
serolog
analysi
use
rapid
caseidentif
subsequ
chain
event
activ
identifi
close
contact
recommend
quarantin
defin
cluster
case
contact
trace
necessari
insuffici
mean
diseas
control
need
care
effort
sensit
time
effect
particularli
highli
dens
popul
shown
singapor
serolog
analysi
use
contact
trace
urban
environ
link
cluster
case
retrospect
delin
transmiss
chain
ascertain
long
transmiss
ongo
estim
proport
asymptomat
individu
popul
beyond
immedi
use
serolog
data
identifi
contain
case
data
also
use
set
control
polici
popul
serolog
test
specif
measur
igg
antibodi
titr
estim
total
number
infect
assess
number
individu
mount
immun
respons
regardless
whether
infect
subclin
happen
recent
past
current
data
suggest
antibodi
persist
least
week
provid
estim
immun
serolog
data
use
least
four
way
first
estim
epidemiolog
variabl
attack
rate
casefat
rate
necessari
assess
much
commun
transmiss
occur
burden
second
strateg
deploy
immun
healthcar
worker
reduc
exposur
viru
suscept
individu
third
assess
effect
nonpharmaceut
intervent
popul
level
inform
polici
chang
releas
measur
fourth
identifi
individu
mount
strong
immunolog
respons
viru
whose
antibodi
isol
use
treat
patient
via
plasma
therapi
although
potenti
serolog
assay
help
control
pandem
substanti
complex
develop
valid
diagnost
test
fulli
elucid
yong
colleagu
serolog
assay
current
develop
widespread
use
yet
sever
challeng
remain
first
assess
sensit
specif
test
particularli
determin
diseas
acut
phase
infect
second
verifi
test
detect
crossreact
viral
pathogen
result
falseposit
result
third
understand
antibodi
kinet
time
distinguish
threshold
immun
know
long
immun
novel
coronaviru
might
last
final
ensur
test
reliabl
distribut
costeffici
although
rtpcr
diagnost
still
